Clinical trial • Phase III • Endocrinology
Retatrutide for Type 2 diabetes mellitus | Diabetes mellitus
Phase III trial of Retatrutide for Type 2 diabetes mellitus | Diabetes mellitus. 95 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 2 diabetes mellitus | Diabetes mellitus
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 14-02-2025
- First CTIS Authorization Date
- 11-04-2025
Trial design
Phase III trial across 1 site in Germany.
- Target Sample Size
- 95
Eligibility
Recruits 95 isVulnerablePopulationSelected = true in CTIS record; no further details on vulnerable population handling, consent, or assent provided in the available documents..
- Vulnerable Population
- isVulnerablePopulationSelected = true in CTIS record; no further details on vulnerable population handling, consent, or assent provided in the available documents.
Recruitment
- Planned Sample Size
- 95
- Recruitment Window Months
- 14
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 95
Germany
- Earliest CTIS Part Ii Submission Date
- 31-03-2025
- Latest Decision Or Authorization Date
- 03-02-2026
- Processing Time Days
- 309
- Number Of Sites
- 1
- Number Of Participants
- 95
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Patrick Fischer
- Contact Person Email
- patrick.fischer@profil.com
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- Retatrutide
Related trials
Other published trials that may interest you.